Van der Auwera P, Pensart N, Korten V, Murray B E, Leclercq R
Service de Médecine et Laboratoire d'Investigation Clinique H. J. Tagnon, (Clinique des Maladies Infectieuses et Laboratoire de Microbiologie), Institut Jules Bordet, Brussels, Belgium.
J Infect Dis. 1996 May;173(5):1129-36. doi: 10.1093/infdis/173.5.1129.
Changes in fecal flora were evaluated in 22 healthy volunteers administered oral vancomycin or teicoplanin in 1989-1991 in Belgium. Evaluation of 5 colonies per subject revealed no glycopeptide-resistant enterococci in the predominant flora before glycopeptide administration; however, large numbers (mostly Enterococcus faecium) emerged by the end of the study in 14 (64%) of the subjects. Pediococci and lactobacilli also increased in number. In 1992, 40 healthy volunteers and 33 cancer patients were evaluated by plating stool samples directly onto selective media containing vancomycin; low numbers of vancomycin-resistant enterococci (< 50 cfu/g) were found in 11 (28%) of the 40 and 4 (12%) of the 33 samples, respectively. DNA restriction fragment length polymorphism analysis showed that most isolates were different, but all contained vanA in Tn1546-like elements. These results indicate that vanA and Tn1546-like elements were common in Belgium as early as 1989 and that community-based individuals in that location likely form a major reservoir for glycopeptide-resistant enterococci.
1989年至1991年期间,在比利时对22名口服万古霉素或替考拉宁的健康志愿者的粪便菌群变化进行了评估。对每名受试者的5个菌落进行评估发现,在给予糖肽类药物之前,优势菌群中没有耐糖肽类肠球菌;然而,到研究结束时,14名(64%)受试者体内出现了大量(主要是粪肠球菌)耐糖肽类肠球菌。片球菌和乳酸菌数量也有所增加。1992年,通过将粪便样本直接接种到含有万古霉素的选择性培养基上,对40名健康志愿者和33名癌症患者进行了评估;在40名受试者的11份样本(28%)和33名患者的4份样本(12%)中分别发现了少量耐万古霉素肠球菌(<50 cfu/g)。DNA限制性片段长度多态性分析表明,大多数分离株不同,但都在Tn1546样元件中含有vanA。这些结果表明,早在1989年vanA和Tn1546样元件在比利时就很常见,而且该地区的社区个体可能是耐糖肽类肠球菌的主要储存库。